01 6Effient
02 2Effient
03 5Efient
04 1Prasugrel
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 3
2019 Revenue in Millions : 5
Growth (%) : -40
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 126
2019 Revenue in Millions : 128
Growth (%) : -1
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 16
2019 Revenue in Millions : 28
Growth (%) : -45
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 133
2020 Revenue in Millions : 126
Growth (%) : 14
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 151
2021 Revenue in Millions : 133
Growth (%) : 14
Main Therapeutic Indication : Cardiovascular
Currency : USD
2015 Revenue in Millions : 522
2014 Revenue in Millions : 523
Growth (%) : 0%
Main Therapeutic Indication : Cardiovascular
Currency : USD
2014 Revenue in Millions : 45.20%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Blood Disorders
Currency : USD
2017 Revenue in Millions : 370
2016 Revenue in Millions : 341
Growth (%) : 9
Main Therapeutic Indication : Blood Disorders
Currency : USD
2018 Revenue in Millions : 202
2017 Revenue in Millions : 347
Growth (%) : -42%
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 535
2015 Revenue in Millions : 523
Growth (%) : 2
LOOKING FOR A SUPPLIER?
